- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Fuji Pharma Acquires 4.2% Stake in Biosimilar Developer Alvotech
This week, Japan-based Fuji Pharma announced that it has acquired a 4.2% stake in Alvotech, a biopharmaceutical company focused on the manufacturing of biosimilars, for roughly $50 million.
This week, Japan-based Fuji Pharma announced that it has acquired a 4.2% stake in Alvotech, a biopharmaceutical company focused on the manufacturing of biosimilars, for roughly $50 million.
The acquisition comes less than 2 months after the companies announced that they had entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan. Under the agreement, Fuji Pharma was offered the opportunity to invest in Alvotech’s capital structure as a way to “establish a long-term relationship.” Through the agreement, Alvotech will be responsible for the development and supply of biosimilars, while Fuji Pharma will be responsible for filing the products with Japan’s regulatory agency, as well as the commercialization of the approved biosimilars.
“We strongly believe that in combining Alvotech’s significant manufacturing capacity and high value biosimilars portfolio with Fuji Pharma’s deep market experience, we will together be staking a place as leaders in Japan’s rapidly growing biosimilar market,” said Rasmus Rojkjaer, CEO of Alvotech.
In order to keep up with anticipatory supply and demand needs, Alvotech recently built a new state-of-the-art biopharmaceutical facility in Reykjavik, Iceland. Additionally, the company owns manufacturing plants in Germany and Switzerland as well, totaling over 13,278 m2.
Alvotech’s biosimilar pipeline consists of 6 monoclonal antibodies for the treatment of cancer, autoimmune diseases, and inflammatory diseases, among others. Alvotech anticipates the first products to be brought to market by 2020.
“Fuji Pharma is extremely pleased to become [a] partner in the growth with Alvotech. At Fuji, we strongly believe in Alvotech’s one-of-a-kind biologics development and scalable manufacturing capabilities,” said Hirofumi Imai, chairman of Fuji Pharma, in a statement.
Other key shareholders in Alvotech include controlling shareholder Aztiq Pharma AB, led by Robert Wessman, founder of Alvotech, and generic pharmaceutical company Alvogen.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
